These two conditions although sharing many clinical and laboratory features are also distinguishable from each other in that they display diVerent ranges of autoantibodies, [3] [4] [5] genetic predisposition, [5] [6] [7] [8] [9] possible reaction to viruses such the Epstein-Barr virus, 8 10-12 and retroviruses. 13 14 Keratoconjunctivitis sicca also develops in older age groups, particularly in those over the age of 80 and has also been recognised in various middle aged patients suVering from Hashimoto's thyroiditis, primary biliary cirrhosis, 15 or in those with no discernible clinical or laboratory disorder.
Three 'ocular' areas are at risk in dry eyed patients-the lacrimal gland, the conjunctiva, and the cornea. Pathology of the lacrimal gland in both primary and secondary Sjögren's syndrome is identical and well documented, from the time of Sjögren's original description to more recent studies of biopsies and postmortem material. 16 How the inflammatory reaction is set oV, of course, remains problematical but in the worst scenario, the gland is replaced with fibrotic tissue following on periods of prolonged massive focal inflammatory infiltration. In the dry eyes of 'old age' fibrotic replacement gradually develops without dramatic massive inflammatory episodes. Some studies, however, indicate that throughout a lifetime the lacrimal gland may suVer from focal areas of perivascular inflammation leading to pockets of fibrosis. 17 In short, there is more than one way to end up with a nonproductive lacrimal gland.
To add to the complexity of the situation, the conjunctival epithelial changes in both primary and secondary Sjögren's syndrome are quite distinctive in that they show stratification of the conjunctival epithelium with a progressive loss of nuclei, fragility of the epithelial surface, as shown in the form of a tendency for separation, and a progressive goblet cell deterioration and loss. In contrast, the dry eye of old age shows patchy atrophy and hyperplasia of the conjunctiva but no sign of stratification though, in common with patients with Sjögren's syndrome, the goblet cells gradually disappear. 18 19 The reasons for conjunctival epithelial dysfunction in these two forms of keratoconjunctivitis sicca, must then be quite diVerent.
In the majority of patients suVering from keratoconjunctivitis sicca, there is no clinical evidence of corneal epithelial involvement. Seventy five per cent of patients show conjunctival interpalpable staining only. However, with a disrupted tear film and a faster than average tear break up time, the corneal surface is at risk.
What can an ophthalmologist hope to contribute in such a complex situation?
Clinical accuracy and diagnosis, provision of samples of tears and tissues for laboratory examination, and careful assessment of changes in signs and symptoms resulting from therapy are all areas in which the interested and committed clinician can participate.
In this month's issue of the BJO (p 533), Yokoi et al present the results of applying hyaluronan to the corneal surface of 11 dry eyed patients, seven of whom had Sjögren's syndrome. In all 11 of their cases dysfunction of the corneal epithelial barrier was recognised by using fluorophotometry. After 2 weeks, hyaluronan treated right corneas showed significant corneal epithelial barrier improvement in the lower portion and after 4 weeks the central cornea also improved. The left corneas treated only with artificial tears showed no improvement at all. The authors conclude that hyaluronan is eVective in the treatment of corneal epithelial disruption in the dry eye. The beauty of this concise and uncomplicated paper is the way in which the authors don't try to answer too many questions at one time. Their claims are modest and indeed they refer to previous studies oVering indiVerent results, particularly from the patient's viewpoint on the use of this substance as a standard therapy.
In the complicated multiaetiological world of dry eyes, diagnostic problems and phases of activity can play havoc with clinical trials. Yokoi et al, in this study, concentrated on specific signs only. Whether hyaluronan will prove to be an eVective treatment, reducing both symptoms and signs, remains to be seen.
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